Stereoselective Process for a CCR3 Antagonist was written by Yue, Tai-Yuen;McLeod, Douglas D.;Albertson, Kevin B.;Beck, Steven R.;Deerberg, Joerg;Fortunak, Joseph M.;Nugent, William A.;Radesca, Lilian A.;Tang, Liya;Xiang, Cathie Dong. And the article was included in Organic Process Research & Development in 2006.Application of 77876-39-2 This article mentions the following:
A convergent, multikilogram, stereoselective synthesis of 1 is described. A key fragment, (S)-3-(4-fluorobenzyl)piperidine (2) was synthesized from valerolactam in three steps using our recently discovered Ir-BDPP-catalyzed asym. hydrogenation. Another key fragment, (1R,2R)-2-(benzyloxycarbonylamino)cyclohexanecarboxaldehyde (3) was synthesized from meso-hexahydrophthalic anhydride in seven steps. The stereochem. was set in the first step of this sequence via a quinidine-mediated desymmetrization of the meso-anhydride. Coupling of the fragments 2 and 3 followed by deprotection provided the penultimate 23. The active pharmaceutical ingredient (API) free base 1 was obtained by treatment of 23 with the aminothiazole fragment 4 under mild conditions. In the experiment, the researchers used many compounds, for example, (2S,4S)-Pentane-2,4-diylbis(diphenylphosphine) (cas: 77876-39-2Application of 77876-39-2).
(2S,4S)-Pentane-2,4-diylbis(diphenylphosphine) (cas: 77876-39-2) belongs to chiral phosphine ligands. Generally, the efficiency of nucleophilic phosphine catalysis often depends on the nature of the tertiary phosphine. Chiral phosphine catalysts: Nucleophilic phosphine catalysis often involves the formation of Lewis adducts, namely phosphonium (di)enolate zwitterions, as reaction intermediates.Application of 77876-39-2
Referemce:
Phosphine ligand,
Chiral phosphines in nucleophilic organocatalysis